The Global Post Acute Myocardial Infarction Market is expected to witness huge growth in the forecast period. Rising cases of hypertension and other cardiovascular diseases boosts the post-acute myocardial infarction market. It is used to prevent or improve symptoms in people who've abnormal coronary heart rhythm, Chest ache, coronary heart assaults, coronary heart failure, migraine, and kinds of tremors. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the post acute myocardial infarction market in the forecast period 2022-2029. The expected CAGR of post acute myocardial infarction market is tend to be around 6.4% in the mentioned forecast period. The market was valued at USD 1816.8 million in 2021, and it would grow up to USD 2984.28 million by 2029.
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Post-acute myocardial infarction is the most common complication of acute myocardial infarction, defined as acute coronary artery closure. It is associated with either rupture of the plaque which leading to acute onset of thrombus formation and certain arrest of blood supply to the particular area. The most frequently witnessed mechanical complications are acute mitral regurgitation secondary to papillary muscle rupture, pseudoaneurysm, ventricular septal defect, and free wall rupture.
Download Exclusive Sample Report (Including Graphs, Charts Table Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-post-acute-myocardial-infarction-market
Global Post-Acute Myocardial Infarction Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of the population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need of physical activity. This boost the market growth.
- Rising Demand for Antibiotics
The increasing demand of different antibiotics resulted in the increase in the market growth. Novel antithrombotics such as NOACs and antiplatelet drugs such as Effient offer substantial advantages, such as target specificity. Some of the major examples under this category include edoxaban (LIXIANA), rivaroxaban, and apixaban (ELIQUIS). It has been observed that Andexxa by Portola Pharmaceuticals is the first and only antidote indicated for the treatment of uncontrolled bleeding caused by rivaroxaban and apixaban.
Opportunities
- Rising Prevalence of Hypertension
As per the American College of Cardiology, older adults are mostly undertreated for high blood pressure, despite having the maximum prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). According to the National Health and Nutrition Examination Survey (NHANES) records in the U.S., hypertension affects 70% of persons over 65 years. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is projected to rise to 20% by 2050. This will create more opportunities for the market growth as the demand for the blockers also increases.
- Increased Product Launches
The rising product launches are adding in much to the growth of the market. The growing number of product approvals and launches is expected to boost the growth of the global myocardial infarction market. For instance, on October 13, 2020, Cadila Pharmaceuticals Ltd., launched Tikacad, which is an antiplatelet drug containing ticagrelor. It is a P2Y12 platelet inhibitor that is believed to reducte the cardiovascular death rate, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or history of myocardial infarction (MI).
Global Post Acute Myocardial Infarction Market Scope
The global post acute myocardial infarction market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antiplatelet Therapy
- Beta Blockers
Acebutolol.
- Atenolol
- Renin-Angiotensin-Aldosterone System Inhibitors
- Angiotensin-converting enzyme inhibitors (ACEIs)
- Angiotensin II receptor blockers (ARBs)
- Statin Therapy
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
To Get a Detailed Table of Contents (TOC), please Click Here at @ https://www.databridgemarketresearch.com/toc/?dbmr=global-post-acute-myocardial-infarction-market
Post-Acute Myocardial Infarction Market Regional Analysis/Insights
The global post acute myocardial infarction market is analyzed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global post acute myocardial infarction market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global post acute myocardial infarction market throughout the forecasted period due to the high prevalence of myocardial infarction and technological advancement in the treatment.
Asia-Pacific dominates the market due to the vulnerable aging population as this group are highly susceptible to cardiovascular disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Post Acute Myocardial Infarction Market Share Analysis
The global post acute myocardial infarction market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global post acute myocardial infarction market
Key players operating in the global post acute myocardial infarction market include:
- Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Group (India)
- Pfizer Inc (U.S.)
- Lupin (India)
- GSK Plc (U.K.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals (U.S.)
- Alnylam Pharmaceuticals, Inc (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
Browse Detailed Summary of Research Report @ https://www.databridgemarketresearch.com/reports/global-post-acute-myocardial-infarction-market
Research Methodology:
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Top Trending’s Reports:-
https://www.databridgemarketresearch.com/reports/global-mri-pulse-oximeters-market
https://www.databridgemarketresearch.com/reports/global-biomarker-translation-services-market
https://www.databridgemarketresearch.com/reports/global-robot-assisted-endoscopy-market
https://www.databridgemarketresearch.com/reports/global-pharmacy-information-systems-market
https://www.databridgemarketresearch.com/reports/global-hereditary-testing-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability levels and advanced approaches. We are committed to uncovering the best consumer prospects and fostering useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expanded its reach by opening a new office in the Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Corporatesales@databridgemarketresearch.com
